ziprasidone has been researched along with Diseases, Metabolic in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Morphy, R; Rankovic, Z | 1 |
| Coolen, HK; Glennon, JC; Kruse, CG; Lange, JH; Reinders, JH; Tolboom, JT | 1 |
| Dai, G; Zhang, Y | 1 |
| Alonso-Martín, C; Arias-Loste, MT; Crespo, J; Crespo-Facorro, B; Fábrega, E; Martínez-García, O; Morlán-Coarasa, MJ; Ortiz-García de la Foz, V; Romero-Gómez, M | 1 |
| Calabrese, JR; Ice, KS; Karayal, ON; Kemp, DE; Pappadopulos, E; Sachs, GS; Siu, CO; Vieta, E | 1 |
| Balbo, E; Delgado, JF; Diez, T; Martin, E; Montes, JM; Rodriguez, JL; Sopelana, P; Soto, JA; Villardaga, I | 1 |
1 review(s) available for ziprasidone and Diseases, Metabolic
| Article | Year |
|---|---|
Designed multiple ligands. An emerging drug discovery paradigm.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Allergic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents; Antihypertensive Agents; Antipsychotic Agents; Chemistry, Pharmaceutical; Dopamine D2 Receptor Antagonists; Drug Design; Humans; Ligands; Metabolic Diseases; Peroxisome Proliferator-Activated Receptors; Receptors, Histamine H1; Selective Serotonin Reuptake Inhibitors | 2005 |
3 trial(s) available for ziprasidone and Diseases, Metabolic
| Article | Year |
|---|---|
Efficacy and metabolic influence of paliperidone ER, aripiprazole and ziprasidone to patients with first-episode schizophrenia through 52 weeks follow-up in China.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Body Mass Index; China; Delayed-Action Preparations; Diagnostic and Statistical Manual of Mental Disorders; Female; Follow-Up Studies; Humans; Hyperglycemia; Hyperlipidemias; Isoxazoles; Male; Metabolic Diseases; Paliperidone Palmitate; Piperazines; Psychiatric Status Rating Scales; Pyrimidines; Quinolones; Schizophrenia; Thiazoles; Weight Gain; Young Adult | 2012 |
Incidence of non-alcoholic fatty liver disease and metabolic dysfunction in first episode schizophrenia and related psychotic disorders: a 3-year prospective randomized interventional study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Incidence; Male; Metabolic Diseases; Middle Aged; Non-alcoholic Fatty Liver Disease; Piperazines; Prospective Studies; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles; Young Adult | 2016 |
Ziprasidone with adjunctive mood stabilizer in the maintenance treatment of bipolar I disorder: long-term changes in weight and metabolic profiles.
Topics: Adjuvants, Immunologic; Antipsychotic Agents; Bipolar Disorder; Body Weight; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Lithium Chloride; Longitudinal Studies; Male; Metabolic Diseases; Metabolome; Piperazines; Psychiatric Status Rating Scales; Thiazoles; Valproic Acid | 2012 |
2 other study(ies) available for ziprasidone and Diseases, Metabolic
| Article | Year |
|---|---|
Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzoxazines; Biogenic Monoamines; Humans; Hyperprolactinemia; Indoles; Metabolic Diseases; Phthalimides; Piperazines; Principal Component Analysis; Pyridines; Radioligand Assay; Receptors, Biogenic Amine; Weight Gain | 2007 |
Improvement in antipsychotic-related metabolic disturbances in patients with schizophrenia switched to ziprasidone.
Topics: Adult; Antipsychotic Agents; Blood Glucose; Body Weight; Cholesterol; Female; Humans; Male; Metabolic Diseases; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Retrospective Studies; Schizophrenia; Severity of Illness Index; Statistics, Nonparametric; Thiazoles; Time Factors | 2007 |